Collegium Pharmaceutical (COLL) News
NASDAQ: COLLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
24.72-0.49 (-1.94%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COLL news summary
We found 14 recent headlines mentioning Collegium Pharmaceutical (COLL): 3 in the past week and 12 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, COLL is down 1.94% at $24.72. The most recent story, "J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Collegium Pharmaceutical headlines
- J&J to Boost Ophthalmology Pipeline With $2.2B Ollin AcquisitionJNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.NasdaqJNJ, COLL, VCEL
- INCY Wins European Commission Nod For Skin Disease DrugIncyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.NasdaqINCY, NVS, COLL
- Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HSNVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.NasdaqNVS, COLL, VCEL, KROS
- NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock DownNektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.NasdaqNKTR, LLY, COLL
- Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity ProgramPFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.NasdaqPFE, COLL, VCEL, AMRX
- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesLiquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.NasdaqLQDA, UTHR, COLL, AMRX
- TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpTG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.NasdaqTGTX, HALO, COLL, AMRX
- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpIronwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.NasdaqIRWD, AZN, ABBV, COLL
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year –GlobeNewswire
- Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineCollegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqCOLL, UTHR
- Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across MassachusettsNew multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership…GlobeNewswire
- HCA Healthcare Q3 Earnings Beat Estimates on Higher AdmissionsHCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.NasdaqHCA, TGTX, GMED, COLL
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…GlobeNewswire
- Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall CongressesSeven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release…GlobeNewswire